文献速递药物不良反应与药物警戒

欧盟2018-2021年风险最小化措施有效性评估中报告的局限性:行业发起上市后安全性研究的定性分析

Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety Studies.
PubMed 文献 · Clin Pharmacol Ther · 2024-07-12

该研究对2018至2021年药物警戒风险评估委员会终审的行业发起上市后安全性研究(PASS)进行定性分析,提取评估报告和研究报告中的研究局限性。39项(61.0%)PASS得出了风险最小化措施(RMM)有效性结论,25项(39.0%)无法得出结论。常见局限性为调查相关偏倚及二手数据缺失或错分,后者在无结论PASS中更常见,提示应在方案阶段通过可行性评估优先缓解二手数据相关局限。

要点

  • 约40%的行业发起PASS无法得出RMM有效性结论。
  • 调查相关选择偏倚和信息偏倚是常见局限性。
  • 二手数据缺失或错分在无结论PASS中更常见。

核心结论

  • 约40%的行业发起PASS无法就RMM有效性得出结论,二手数据相关局限性在无结论研究中更常见。
  • 建议在方案阶段通过可行性评估等策略优先缓解二手数据相关局限性,以助达成研究目标并得出RMM有效性结论。

研究设计与样本

  • 对2018至2021年药物警戒风险评估委员会终审的行业发起PASS的评估报告和研究报告中的研究局限性进行主题分析。
  • 共分析PASS中39项(61.0%)得出RMM有效性结论,25项(39.0%)无结论。
  • 多数PASS为横断面设计(73.4%),以调查为主要数据来源(65.6%)。

主要发现

  • 共归纳四个主题:调查特异性局限性、二手数据使用相关局限性、研究设计一般局限性、非研究设计相关局限性。
  • 常见局限性为调查相关偏倚,如选择偏倚或信息偏倚。
  • 二手数据缺失或错分等已知局限性在无结论PASS中比有结论PASS更常报告。

临床怎么用

  • 设计行业发起PASS评估RMM有效性时,应在方案阶段开展可行性评估以识别并缓解二手数据缺失或错分等局限。
  • 对以调查为主要数据来源的PASS,需预先考虑选择偏倚和信息偏倚的缓解策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Marketing-authorization holders evaluate the effectiveness of risk minimization measures (RMM) for medicines through the conduct of post-authorization safety studies (PASS). Earlier studies show that concluding on RMM effectiveness is challenging. The aim of this study was to describe reported limitations associated with RMM effectiveness assessments of industry-sponsored PASS that did not render a conclusion. We conducted a thematic analysis of study limitations extracted from assessment reports and study reports finalized by the Pharmacovigilance Risk Assessment Committee between 2018 and 2021. In 39 (61.0%) of the PASS a conclusion on RMM effectiveness was drawn, where 25 (39.0%) PASS was inconclusive. Most PASS had a cross-sectional design with surveys as primary data sources (73.4% and 65.6% respectively). Four main themes emerged: (i) survey-specific limitations, (ii) limitations specifically related to secondary use of data, (iii) general limitations related to study design, and (iv) limitations not related to study design. In general, frequently reported limitations were survey-related, such as selection bias or information bias. Interestingly, well-known study limitations related to secondary use of data such as missing or misclassification of data were more often presented in inconclusive compared with conclusive PASS. Given that about 40% of PASS did not allow a conclusion on RMM effectiveness, our results suggest prioritization for strategies to mitigate limitations related to the secondary use of data at the protocol stage, for example, through feasibility assessments. Although many databases may have incomplete registration of some variables, feasibility testing prior to conducting a PASS could contribute to meeting study objectives and concluding on RMM effectiveness.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Grupstra RJ, Goedecke T, Gardarsdottir H, et al. Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety Studies. Clin Pharmacol Ther. 2024. PMID: 38994581. doi:10.1002/cpt.3369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。